State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Mol Cell Biochem. 2011 Feb;348(1-2):141-7. doi: 10.1007/s11010-010-0648-6. Epub 2010 Nov 16.
Platinum-based chemotherapy, such as cisplatin, is the primary treatment for human ovarian cancer. However, overcoming drug resistance has become an important issue in cancer chemotherapy. In this study, we performed 2-DE and ESI-Q-TOF MS/MS analysis to identify differential proteins expression between cisplatin-sensitive (A2780S) and cisplatin-resistant (A2780-CP) ovarian cancer cell lines. Of the 14 spots identified as differentially expressed (±over twofold, P < 0.05) between the two cell lines, ten spots (corresponding to ten unique proteins) were positively identified by ESI-Q-TOF MS/MS analysis. These proteins include capsid glycoprotein, fructose-bisphosphate aldolase C, heterogeneous nuclear ribonucleoproteins A2/B1, putative RNA-binding protein 3, Ran-specific GTPase-activating protein, ubiquitin carboxyl-terminal hydrolase isozyme L1, stathmin, ATPSH protein, chromobox protein homolog3 and phosphoglycerate kinase 1. The proteins identified in this study would be useful in revealing the mechanisms underlying cisplatin resistance and also provide some clues for further research.
基于铂的化疗，如顺铂，是治疗人类卵巢癌的主要方法。然而，克服耐药性已成为癌症化疗中的一个重要问题。在这项研究中，我们进行了 2-DE 和 ESI-Q-TOF MS/MS 分析，以鉴定顺铂敏感（A2780S）和耐药（A2780-CP）卵巢癌细胞系之间差异表达的蛋白质。在两个细胞系之间差异表达（±两倍以上，P < 0.05）的 14 个斑点中，通过 ESI-Q-TOF MS/MS 分析鉴定出了 10 个斑点（对应 10 种独特的蛋白质）。这些蛋白质包括衣壳糖蛋白、果糖-二磷酸醛缩酶 C、异质核核糖核蛋白 A2/B1、假定的 RNA 结合蛋白 3、Ran 特异性 GTP 酶激活蛋白、泛素羧基末端水解酶同工酶 L1、stathmin、ATPSH 蛋白、同源盒蛋白 3 和磷酸甘油酸激酶 1。本研究中鉴定的蛋白质将有助于揭示顺铂耐药的机制，并为进一步研究提供一些线索。
